Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur MARIE-HELENE LOVAT-NOEL

LibéralRPPS 10002911666

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

📝 Autres formations

  • DEES Rhumatologie

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease

    Cell reports · 2021

    📚 173 citations🎯 RCR 11.05Top 2% NIH🔓 Open Access📄 PDF gratuit ↗
  • 2
    Age-related shift in LTD is dependent on neuronal adenosine A(2A) receptors interplay with mGluR5 and NMDA receptors

    Molecular psychiatry · 2020

    📚 142 citations🎯 RCR 8.28Top 3% NIH🔓 Open Access📄 PDF gratuit ↗
  • 3
    Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model

    International journal of molecular sciences · 2020

    📚 27 citations🎯 RCR 1.46🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Therapeutic approaches providing effective medication for Alzheimer’s disease (AD) patients after disease onset are urgently needed. Previous studies in AD mouse models suggested that physical exercise or changed lifestyle can delay AD-related synaptic and memory dysfunctions when treatment started in juvenile animals long before onset of disease symptoms, while a pharmacological treatment that can reverse synaptic and memory deficits in AD mice was thus far not identified. Repurposing food and drug administration (FDA)-approved drugs for treatment of AD is a promising way to reduce the time to bring such medication into clinical practice. The sphingosine-1 phosphate analog fingolimod (FTY720) was approved recently for treatment of multiple sclerosis patients. Here, we addressed whether fingolimod rescues AD-related synaptic deficits and memory dysfunction in an amyloid precursor protein/presenilin-1 (APP/PS1) AD mouse model when medication starts after onset of symptoms (at five months). Male mice received intraperitoneal injections of fingolimod for one to two months starting at five to six months. This treatment rescued spine density as well as long-term potentiation in hippocampal cornu ammonis-1 (CA1) pyramidal neurons, that were both impaired in untreated APP/PS1 animals at six to seven months of age. Immunohistochemical analysis with markers of microgliosis (ionized calcium-binding adapter molecule 1; Iba1) and astrogliosis (glial fibrillary acid protein; GFAP) revealed that our fingolimod treatment regime strongly down regulated neuroinflammation in the hippocampus and neocortex of this AD model. These effects were accompanied by a moderate reduction of Aβ accumulation in hippocampus and neocortex. Our results suggest that fingolimod, when applied after onset of disease symptoms in an APP/PS1 mouse model, rescues synaptic pathology that is believed to underlie memory deficits in AD mice, and that this beneficial effect is mediated via anti-neuroinflammatory actions of the drug on microglia and astrocytes.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal31

▼

Arthrite juvénile2

▼

Vascularites des gros vaisseaux2

▼

Anti-IL-171

▼

csDMARDs1

▼

Économie santé1

▼

Épidémiologie & registres1

▼

Essai clinique1

▼

Génétique1

▼

JAK inhibiteurs1

▼

Lombalgie1

▼

Lupus1

▼

Maladie à IgG41

▼

Qualité de vie / PROMs1

▼

Revue générale1

▼

Sjögren1

▼

Vascularites1

▼

Vraie vie / RWE1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.